Matches in SemOpenAlex for { <https://semopenalex.org/work/W1998399623> ?p ?o ?g. }
- W1998399623 endingPage "1259" @default.
- W1998399623 startingPage "1251" @default.
- W1998399623 abstract "Abstract Objective: This subgroup analysis sought to determine the efficacy and tolerability of a 5-day regimen of levofloxacin 750 mg/d compared with a 10-day regimen of levofloxacin 500 mg/d in the treatment of community-acquired pneumonia (CAP) in elderly patients (aged ≥65 years). Methods: This subgroup analysis was based on the outcomes in patients aged ≥65 years from a randomized, double-blind, controlled trial conducted at 70 US centers. Patients in Pneumonia Severity Index (PSI) class I/II and III/IV were randomized to receive levofloxacin 750 mg/d for 5 days or levofloxacin 500 mg/d for 10 days. Study investigators assessed clinical and microbiologic outcomes 7 to 14 days after administration of the last dose of medication and collected adverse events for 30 days after the last dose. Results: This analysis included 177 elderly patients, 80 receiving levofloxacin 750 mg/d for 5 days and 97 receiving levofloxacin 500 mg/d for 10 days. Although most demographic and baseline clinical characteristics were comparable between the 2 groups, the group that received levofloxacin 500 mg/d was older than the group that received levofloxacin 750 mg/d (median age, 76.0 vs 72.5 years, respectively; P = 0.029) and had a higher mean PSI score (90.7 vs 83.1; P = 0.017). Despite the halved duration of therapy, unadjusted clinical success rates were comparable between the 2 groups (89.0% and 91.9% in the 750- and 500-mg arms, respectively; 95% CI, −7.1 to 12.7). Microbiologic eradication rates were 90.3% (28/31) in the 750-mg arm and 87.5% (14/16) in the 500-mg arm (P = NS). Multivariate analysis adjusting for baseline PSI score indicated that treatment assignment was not statistically associated with clinical success (adjusted odds ratio for clinical success with 500-mg dose, 1.92; 95% CI, 0.62 to 5.99). The incidence of treatment-emergent adverse events did not differ between the 2 study treatments. The most common adverse events in both groups were insomnia, constipation, and headache. Conclusions: This subgroup analysis found that levofloxacin 750 mg/d for 5 days was well tolerated in the treatment of CAP in elderly patients. Undajusted and adjusted rates of clinical success were statistically similar between levofloxacin 750 mg/d for 5 days and levofloxacin 500 mg/d for 10 days. Abstract This subgroup analysis sought to determine the efficacy and tolerability of a 5-day regimen of levofloxacin 750 mg/d compared with a 10-day regimen of levofloxacin 500 mg/d in the treatment of community-acquired pneumonia (CAP) in elderly patients (aged ≥65 years). This subgroup analysis was based on the outcomes in patients aged ≥65 years from a randomized, double-blind, controlled trial conducted at 70 US centers. Patients in Pneumonia Severity Index (PSI) class I/II and III/IV were randomized to receive levofloxacin 750 mg/d for 5 days or levofloxacin 500 mg/d for 10 days. Study investigators assessed clinical and microbiologic outcomes 7 to 14 days after administration of the last dose of medication and collected adverse events for 30 days after the last dose. This analysis included 177 elderly patients, 80 receiving levofloxacin 750 mg/d for 5 days and 97 receiving levofloxacin 500 mg/d for 10 days. Although most demographic and baseline clinical characteristics were comparable between the 2 groups, the group that received levofloxacin 500 mg/d was older than the group that received levofloxacin 750 mg/d (median age, 76.0 vs 72.5 years, respectively; P = 0.029) and had a higher mean PSI score (90.7 vs 83.1; P = 0.017). Despite the halved duration of therapy, unadjusted clinical success rates were comparable between the 2 groups (89.0% and 91.9% in the 750- and 500-mg arms, respectively; 95% CI, −7.1 to 12.7). Microbiologic eradication rates were 90.3% (28/31) in the 750-mg arm and 87.5% (14/16) in the 500-mg arm (P = NS). Multivariate analysis adjusting for baseline PSI score indicated that treatment assignment was not statistically associated with clinical success (adjusted odds ratio for clinical success with 500-mg dose, 1.92; 95% CI, 0.62 to 5.99). The incidence of treatment-emergent adverse events did not differ between the 2 study treatments. The most common adverse events in both groups were insomnia, constipation, and headache. This subgroup analysis found that levofloxacin 750 mg/d for 5 days was well tolerated in the treatment of CAP in elderly patients. Undajusted and adjusted rates of clinical success were statistically similar between levofloxacin 750 mg/d for 5 days and levofloxacin 500 mg/d for 10 days." @default.
- W1998399623 created "2016-06-24" @default.
- W1998399623 creator A5010704361 @default.
- W1998399623 creator A5016904566 @default.
- W1998399623 creator A5020757594 @default.
- W1998399623 creator A5022529470 @default.
- W1998399623 creator A5077718840 @default.
- W1998399623 date "2005-08-01" @default.
- W1998399623 modified "2023-09-28" @default.
- W1998399623 title "A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged ≥65 years with community-acquired pneumonia" @default.
- W1998399623 cites W1591234936 @default.
- W1998399623 cites W1843993979 @default.
- W1998399623 cites W1947015332 @default.
- W1998399623 cites W1950073785 @default.
- W1998399623 cites W1971220651 @default.
- W1998399623 cites W1983076976 @default.
- W1998399623 cites W2019988983 @default.
- W1998399623 cites W2027453508 @default.
- W1998399623 cites W2040816640 @default.
- W1998399623 cites W2059530273 @default.
- W1998399623 cites W2106676541 @default.
- W1998399623 cites W2113256741 @default.
- W1998399623 cites W2116117562 @default.
- W1998399623 cites W2123324969 @default.
- W1998399623 cites W2140087978 @default.
- W1998399623 cites W2142191165 @default.
- W1998399623 cites W2142230428 @default.
- W1998399623 cites W2158956796 @default.
- W1998399623 cites W2166754635 @default.
- W1998399623 cites W2320270386 @default.
- W1998399623 cites W32772181 @default.
- W1998399623 cites W4256215782 @default.
- W1998399623 doi "https://doi.org/10.1016/s0149-2918(05)80214-0" @default.
- W1998399623 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16199249" @default.
- W1998399623 hasPublicationYear "2005" @default.
- W1998399623 type Work @default.
- W1998399623 sameAs 1998399623 @default.
- W1998399623 citedByCount "38" @default.
- W1998399623 countsByYear W19983996232012 @default.
- W1998399623 countsByYear W19983996232013 @default.
- W1998399623 countsByYear W19983996232014 @default.
- W1998399623 countsByYear W19983996232015 @default.
- W1998399623 countsByYear W19983996232016 @default.
- W1998399623 countsByYear W19983996232017 @default.
- W1998399623 countsByYear W19983996232018 @default.
- W1998399623 countsByYear W19983996232019 @default.
- W1998399623 crossrefType "journal-article" @default.
- W1998399623 hasAuthorship W1998399623A5010704361 @default.
- W1998399623 hasAuthorship W1998399623A5016904566 @default.
- W1998399623 hasAuthorship W1998399623A5020757594 @default.
- W1998399623 hasAuthorship W1998399623A5022529470 @default.
- W1998399623 hasAuthorship W1998399623A5077718840 @default.
- W1998399623 hasConcept C126322002 @default.
- W1998399623 hasConcept C141071460 @default.
- W1998399623 hasConcept C168563851 @default.
- W1998399623 hasConcept C187960798 @default.
- W1998399623 hasConcept C197934379 @default.
- W1998399623 hasConcept C2776102371 @default.
- W1998399623 hasConcept C2777914695 @default.
- W1998399623 hasConcept C2778314733 @default.
- W1998399623 hasConcept C2778375690 @default.
- W1998399623 hasConcept C2781276175 @default.
- W1998399623 hasConcept C2781413609 @default.
- W1998399623 hasConcept C44249647 @default.
- W1998399623 hasConcept C501593827 @default.
- W1998399623 hasConcept C535046627 @default.
- W1998399623 hasConcept C71924100 @default.
- W1998399623 hasConcept C86803240 @default.
- W1998399623 hasConcept C89423630 @default.
- W1998399623 hasConceptScore W1998399623C126322002 @default.
- W1998399623 hasConceptScore W1998399623C141071460 @default.
- W1998399623 hasConceptScore W1998399623C168563851 @default.
- W1998399623 hasConceptScore W1998399623C187960798 @default.
- W1998399623 hasConceptScore W1998399623C197934379 @default.
- W1998399623 hasConceptScore W1998399623C2776102371 @default.
- W1998399623 hasConceptScore W1998399623C2777914695 @default.
- W1998399623 hasConceptScore W1998399623C2778314733 @default.
- W1998399623 hasConceptScore W1998399623C2778375690 @default.
- W1998399623 hasConceptScore W1998399623C2781276175 @default.
- W1998399623 hasConceptScore W1998399623C2781413609 @default.
- W1998399623 hasConceptScore W1998399623C44249647 @default.
- W1998399623 hasConceptScore W1998399623C501593827 @default.
- W1998399623 hasConceptScore W1998399623C535046627 @default.
- W1998399623 hasConceptScore W1998399623C71924100 @default.
- W1998399623 hasConceptScore W1998399623C86803240 @default.
- W1998399623 hasConceptScore W1998399623C89423630 @default.
- W1998399623 hasIssue "8" @default.
- W1998399623 hasLocation W19983996231 @default.
- W1998399623 hasLocation W19983996232 @default.
- W1998399623 hasOpenAccess W1998399623 @default.
- W1998399623 hasPrimaryLocation W19983996231 @default.
- W1998399623 hasRelatedWork W1572305784 @default.
- W1998399623 hasRelatedWork W1998399623 @default.
- W1998399623 hasRelatedWork W2029978358 @default.
- W1998399623 hasRelatedWork W2063423899 @default.
- W1998399623 hasRelatedWork W2125209012 @default.
- W1998399623 hasRelatedWork W2355268680 @default.
- W1998399623 hasRelatedWork W2356136355 @default.